Other studies also reported similar UTI rates between treatment groups [31, 37, 52, 53] while a pooled analysis (OR 1.15; 95% CI 1.00, 1.33; p = 0.047) [38] and a retrospective cohort study in Korea (HR 1.05; 95% CI 1.00, 1.11; p = 0.047) [54] reported increased risk of UTIs with SGLT2 inhibitors which was borderline significant. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.